464 related articles for article (PubMed ID: 26190670)
1. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone?
Plent S; Mitchell M; Fan W; Werner R
Hosp Pract (1995); 2015; 43(3):164-71. PubMed ID: 26190670
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
Pinto DS; Ogbonnaya A; Sherman SA; Tung P; Normand SL
Circ Cardiovasc Qual Outcomes; 2012 Jan; 5(1):52-61. PubMed ID: 22235065
[TBL] [Abstract][Full Text] [Related]
3. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
Kaul U; Dua A; Sethi AK; Arambam P; Seth A
Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
7. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
Borg S; Persson U; Allikmets K; Ericsson K
Clin Ther; 2006 Nov; 28(11):1947-59. PubMed ID: 17213015
[TBL] [Abstract][Full Text] [Related]
8. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.
Zeymer U; van 't Hof A; Adgey J; Nibbe L; Clemmensen P; Cavallini C; ten Berg J; Coste P; Huber K; Deliargyris EN; Day J; Bernstein D; Goldstein P; Hamm C; Steg PG
Eur Heart J; 2014 Sep; 35(36):2460-7. PubMed ID: 24849104
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
[TBL] [Abstract][Full Text] [Related]
15. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Patel D; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28855222
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
[TBL] [Abstract][Full Text] [Related]
19. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.
Fabris E; Kilic S; Van't Hof AWJ; Ten Berg J; Ayesta A; Zeymer U; Hamon M; Soulat L; Bernstein D; Anthopoulos P; Deliargyris EN; Steg PG
JAMA Cardiol; 2017 Jul; 2(7):791-796. PubMed ID: 28273285
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]